Flat sales

Published: 2-Aug-2002


Schering-Plough has reported flat sales for the full-year 2001 of US$8.4bn (€9.6bn), although higher sales were reported for the antihistamine Claritin, which grew by 5% to $3.2bn (€3.6bn). The Intron franchise was up 6% to $1.4bn and sales of Temodar, for brain tumours, was 49% higher at $180m (€205.34m).

Compared with 2001, the company expects a percentage increase in earnings per share in double digits for 2002.

Schering-Plough incurred a $500m (€570.4m) fine during the fourth quarter of last year for deficiencies at its New Jersey and Puerto Rico plants, which contributed to what chairman and ceo Richard Jay Kogan called a 'difficult year for Schering-Plough.'

You may also like